Searched for
CIPLA CASE
Popularity was never my goal; what matters is public health: FDA Commissioner Tukaram MundheMaharashtra FDA Commissioner Tukaram Mundhe prioritizes public health over personal popularity. He has taken action against 12,083 establis...- Tukaram Mundhe cracks down: Maharashtra FDA cancels licence of Cipla's Pune unit over regulatory violations, Cipla contests actionMaharashtra FDA cancelled Cipla's Pune C&F unit drug sale licenses due to serious storage and recall issues. Inspectors found unauthorized ...
- FDA buckles under HC heat, revives Mumbai Cricket Association's suspended eateries after fresh inspectionThe Bombay High Court warned food officials, leading to a license suspension withdrawal. Restaurants on Mumbai Cricket Association premises...
- Q1 Earnings Scorecard: Strong demand drives revenue, input costs hit profitsSustained market demand led to impressive revenue growth in the automotive and consumer goods sectors. In contrast, while the banking secto...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- D-St set for a negative opening as GIFT Nifty signals weak startDomestic equities extended losses for a fourth consecutive session, with the Nifty declining. Investor sentiment remained fragile amid a sh...
- Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practicalUS President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...
- Why did market fall today? 7 triggers behind Rs 4 lakh crore wealth wipeoutIndian stock markets experienced significant declines on Wednesday. Escalating Iran-US tensions and tariff threats spooked investors, causi...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- Cipla gets Rs 773 crore demand notice from I-T departmentThe additional demand was raised for disallowances related to deduction of profits and gains derived from the business of developing, maint...
- Onbrez case: Delhi High Court reserves decision on Novartis-Cipla patent disputeDelhi High Court has reserved its decision on a high-profile patent case that pitted Swiss drug maker Novartis against Cipla over its respi...
- Cipla-Novartis patent row: DIPP looking into merit of caseNovartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent off...
- Cipla’s patent win against Roche boosts hopes of generic drugmakersThe Delhi HC ruling favouring India’s second largest drugmaker Cipla has come as a shot in the arm for other generic makers who are fightin...
- Cipla makes cancer drug cheaperCipla has launched a copycat version of German pharma company Bayer’s cancer medicine Nexavar at one-tenth the price.
- Bayer drags Cipla to court over patentGerman drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- Cipla gets relief as SC rejects Roche pleaThe Supreme Court on Friday rejected Swiss drugmaker Roche’s petition to stop Indian firm Cipla from selling the generic version of its can...
- SC asks Roche not to pursue Cipla case until patent examinationThe Supreme Court (SC) has asked Swiss company Roche not to pursue the patent violation case against the generic version of Cipla’s anti-in...
- HC allows CPAA to join Bayer-Cipla caseThe Delhi High Court (HC) has allowed cancer patient group Cancer Patients Aid Association (CPAA) to join the Bayer AG and Cipla case.
- HC breather for Roche in Cipla caseRoche has received a breather with the Bombay High Court granting company's request for an injunction against Cipla.
- Roche sues Cipla over Valcyte patent breachSwiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark ...
Load More
